[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intermittent-fasting\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intermittent-fasting":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,47,74,97,124,154,184,212,242,268,297,323],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100640051","effects-of-timed-restricted-eating-on-body-composition-metabolism-and-cardiovascular-health-100640051",false,"NCT07574177","Effects of Timed Restricted Eating on Body Composition, Metabolism, and Cardiovascular Health","The Effect of Timed Restricted Eating With or Without Intermittent Energy Restriction on Measures of Body Composition, Resting Energy Expenditure, Cardiovascular Modulation, and Blood Biomarkers Over 12 Weeks","Inclusion Criteria:\n\n* Between 18 and 65 years of age\n* Body mass index (BMI) of 26 kg\u002Fm² or higher (overweight or obese range)\n* Physically inactive, defined as 150 minutes or less of moderate-intensity physical activity per week for the 3 months prior to enrollment\n* No previous history of cardiovascular disease or Type 1 or Type 2 Diabetes Mellitus\n* Not currently taking medications that may affect blood sugar, cholesterol, or body weight (e.g., glucose-lowering drugs, statins, or weight loss medications)\n* Weight stable, defined as no more than 5 kg (about 11 lbs.) of body weight change in the 3 months prior to enrollment\n* Willing and able to follow the study requirements, provide voluntary consent, and complete all study procedures\n\nExclusion Criteria:\n\n* Younger than 18 or older than 65 years of age\n* BMI below 26 kg\u002Fm²\n* More than 150 minutes per week of moderate-intensity physical activity in the past 3 months\n* History of cardiovascular disease or Type 1 or Type 2 Diabetes Mellitus\n* Currently taking medications that may impact study outcomes\n* Weight change of more than 5 kg in the past 3 months\n* Pregnant, breastfeeding, or planning to become pregnant during the study\n* History of an eating disorder\n* Previous weight loss surgery (e.g., gastric bypass or sleeve gastrectomy)\n* Unable to fast for approximately 18 hours at a time due to a medical condition\n* Currently working night shifts\n* Has a pacemaker or any implanted electronic device (due to bioimpedance spectroscopy testing)\n* Any health condition the research team determines would put the participant at risk",true,"ALL","18 Years","65 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study is looking at whether eating all meals within a 6-hour window each day (called Time-Restricted Eating, or TRE) can improve body composition, metabolism, heart health, and blood markers over 12 weeks. The study also wants to find out whether allowing participants to eat normally on weekends makes the diet easier to follow long-term.\n\nAdults aged 18-65 with a BMI of 26 or higher who do not have heart disease or diabetes may be eligible. Participants will be randomly placed into one of two groups: (1) TRE every day for 12 weeks, or (2) TRE on weekdays with normal eating on weekends. All participants will visit the lab twice - once at the start and once at the end - for measurements of body fat, resting calorie burn, heart function, and blood tests. Between visits, participants will log their meals and steps at home and check in with the research team every two weeks.",[28],"Intermittent Fasting",[30,31,32,33,34],"Time-Restricted Eating","body composition","obesity","weight management","intermittent fasting","NOT_YET_RECRUITING","2026-05-07",{"date":38,"type":39},"2026-05-12","ACTUAL",{"date":41,"type":22},"2026-07",{"date":43,"type":22},"2027-07",{"name":45,"class":46},"University of South Alabama","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100409100","intermittent-fasting-to-improve-insulin-secretion-100409100","NCT04607096","Intermittent Fasting to Improve Insulin Secretion","IFIS","Inclusion Criteria:\n\n* Body mass index (BMI) between 25 - 40 kg\u002Fm²\n* Understand and voluntarily sign an informed consent document prior to any study related assessments\u002Fprocedures.\n* Subjects with prediabetes (IFG and\u002For IGT, HbA1c 5,4 % - 6,4 %, subphenotype cluster 3 or 5) or\n* Subjects with type 2 diabetes mellitus (diagnosed \\\u003C5 years prior to screening), HbA1c 6.0% - 9.5%, not receiving insulin or thiazolidinediones, and with an appropriate washout period for all other antidiabetic medications)\n\nExclusion Criteria:\n\n* Subjects with diabetes mellitus type 1 (GAD-, IA2-AB positive)\n* Women during pregnancy and lactation\n* Treamtent with any medication effecting on glucose metabolism like anti-diabetic drugs or steroids\n* Subjects with a haemoglobin (Hb) ≤ 11.5 g\u002Fdl (for males) and Hb ≤ 10.5 g\u002Fdl (for females) at screening\n* Any pancreatic disease\n* Medical history of cancer and\u002For treatment for cancer within the last 5 years.\n* Known current presence or history of severe neurological or psychiatric diseases, schizophrenia, bipolar disorder\n* Known history of bariatric surgery\n* Severe liver or kidney diseases (Alanine Aminotransferase (ALT \\[SGPT\\]), Aspartate Aminotransferase (AST \\[SGOT\\]) above 3 x upper limit of normal (ULN) or Glomerular Filtration Rate (eGFR) ≤ 60 ml\u002Fmin (MDRD formula)\n* Systemic infection (CRP \\> 1 mg\u002Fdl)\n* Severe diabetic complications like chronic kidney disease (CKD), proliferating retinopathy or symptomatic cardiovascular disease\n* Presence of any contraindication for the conduct of an MRI investigation, such as cardiac pacemakers, ferromagnetic haemostatic clips in the central nervous system, metallic splinters in the eye, ferromagnetic or electronically operated active devices like automatic cardioverter defibrillators, cochlear implants, insulin pumps and nerve stimulators, prosthetic heart valves etc.\n* Persons with limited temperature sensation and \u002F or elevated sensitivity to warming of the body\n* Persons with a hearing disorder or a increased sensitivity for loud noises\n* Claustrophobia\n* Participation in other clinical trials or observation period of competing trials up to 30 days prior to this study\n* Refusal to get informed of unexpected detected pathological findings","70 Years",{"count":56,"type":22},200,[25],"Type 2 diabetes (T2D) mellitus is a challenge for health care systems as the numbers increases constantly. In 2014, 422 million people had been living with diabetes worldwide. The absolute numbers of people with prediabetes have also grown substantially over 25 years worldwide. In Germany, about 10% of the population has T2D and another 21 % of the population has prediabetes.Overall, 16% of all deaths in Germany are attributable to type 2 diabetes. Macro- and microvascular complications of diabetes imply a significant threat for the patients and are already present in the prediabetic state. Short term and long term complications, the burden of treatment, and reduced quality of life are major burdens of the disease. Accumulating data indicate that currently recommended therapeutic diet regimens in patients with obesity and diabetes are not sustainable on the long term. Novel concepts are therefore urgently needed.\n\nT2D occurs when insulin secretion from pancreatic beta-cells cannot sufficiently be increased to compensate for insulin resistance. Causes of beta-cell dysfunction are heterogeneous. In addition, the most important determinants of diabetes remission are the extend of weight loss and restoration of beta-cell function. In the course of diabetes progression, the inability to recover insulin secretion might identify the state of no return to normal glucose tolerance. It is therefore crucial to improve insulin secretion in treatment and prevention of diabetes. Up to now lifestyle intervention trials in prediabetes or pharmacological intervention trials in diabetes did not show improvement of insulin secretion after intervention. However, one recent small human trial shows that intermittent fasting (early time restricted fasting) is able to improve insulin secretion.Currently, there are no trials that examine the effect of intermittent fasting in individuals with a broad range of impaired glucose metabolism (from prediabetes to diabetes). Recently novel subtypes of diabetes and prediabetes with high risk for the early manifestation of diabetes complications have been identified. Currently, prevention strategies for this high risk individuals have not been examined yet. We will study for the first time the effectiveness of 4 weeks intermittent fasting on changes in insulin secretion capacity in subphenotypes of diabetes and in prediabetes.",[60,61,28,62],"PreDiabetes","Diabetes type2","Insulin Secretion","RECRUITING","2026-04-20",{"date":66,"type":39},"2026-04-21",{"date":68,"type":39},"2021-04-08",{"date":70,"type":22},"2027-03-01",{"name":72,"class":46},"University Hospital Tuebingen",8,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100632394","evaluating-intermittent-fasting-in-individuals-at-high-risk-forpancreatic-cancer-undergoing-screening-100632394","NCT07513116","Evaluating Intermittent Fasting In Individuals At High Risk ForPancreatic Cancer Undergoing Screening","Inclusion Criteria\n\n* Participants ≥ 18 years old. Participants under 18 are excluded due to their potential inability to understand and consent independently to the methods required for the study drug use and its potential risks and benefits.\n* Participants evaluated and classified as high risk for pancreatic cancer through a High-Risk Pancreatic Cancer Clinic or High-Risk Pancreatic Cyst Clinic, based on established clinical assessment and risk stratification.\n* High-risk status may include one or more of the following:\n\n  * Hereditary cancer syndromes or known pathogenic germline mutations associated with pancreatic cancer risk\n  * Family history of pancreatic ductal adenocarcinoma (PDAC)\n  * Presence of pancreatic cysts or precursor lesions (e.g., IPMN, MCN)\n  * New-onset diabetes mellitus is considered suspicious for pancreatic cancer\n  * History of recurrent or chronic pancreatitis\n* Eligibility and surveillance risk assessment must be consistent with NCCN (National Comprehensive Cancer Network) Guidelines for Pancreatic Cancer Screening in High- Risk Individuals.\n* Participants are able to understand and are willing to sign a written informed consent document.\n* Both English-speaking and non-English-speaking participants are eligible for participation\n* Participants are willing to make a change in eating time patterns.\n* Participants are willing to provide App-tracked fasting time data over the course of the study.\n\nExclusion Criteria\n\n* BMI \\\u003C 18.5 Kg\u002Fm2\n* Documented history of symptomatic hypoglycemia\n* Pregnant or breastfeeding women\n* Cognitively impaired individuals",{"count":81,"type":22},20,[25],"To learn whether an eating pattern called intermittent fasting (IF) is tolerable and feasible for individuals at high risk of pancreatic cancer and whether IF is associated with changes in biological markers, including metabolic, inflammatory, microbiome, and imaging-related markers.",[85,28,86],"Evaluating","Pancreatic Cancer","2026-04-13",{"date":89,"type":39},"2026-04-14",{"date":91,"type":22},"2026-09-17",{"date":93,"type":22},"2029-03-30",{"name":95,"class":46},"M.D. Anderson Cancer Center",1,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":16,"sex":103,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":23,"phases":108,"briefSummary":109,"conditions":110,"keywords":113,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":96},"100629964","impact-of-intermittent-fasting-on-the-mental-health-of-perimenopausal-women-100629964","NCT07481513","Impact of Intermittent Fasting on the Mental Health of Perimenopausal Women","Inclusion Criteria:\n\n* Participants eligible in this study will be women between the ages of 45 and 55 who are in the perimenopausal stage as defined by the STRAW criteria and confirmed using the Menopausal Rating Scale (MRS).\n\nExclusion Criteria:\n\n* Currently using hormone replacement therapy\n* Diagnosed with severe medical conditions that could interfere with fasting, including uncontrolled diabetes, heart disease, hypertension, cancer or kidney disease\n* Have a current formal mental health diagnosis as defined by the DSM-5, regardless of whether they are receiving medication or therapy\n* Experiencing any form of dementia\n* Have undergone surgical menopause, have premature ovarian failure, are currently undergoing chemotherapy or radiotherapy, or are ovarian cancer survivors\n* Are currently pregnant. undergoing treatment for endometriosis, have significant thyroid disorders, or are on any form of hormone therapy\n* Do not speak English\n* Participants who score greater than 0 on question 9 of the PHQ-9 (including suicidal ideation) will be removed from the trial and provided with mental health referrals to NGOs for support.","FEMALE","45 Years","55 Years",{"count":107,"type":22},140,[25],"This study will explore how intermittent fasting (specifically the 16\u002F8 method) affects the mental health of women who are in the perimenopause stage. This life stage often brings hormonal changes that can impact emotional and physical well-being. The study will include 98 women aged 45-55, who will be randomly divided into two groups. The study will compare the mental health outcomes of those who follow intermittent fasting with those who do not, using independent t-tests to analyze the results. The goal is to better understand if intermittent fasting can help improve mental health during perimenopause.",[111,112,28],"Mental Health","Perimenopause",[28,111,112,114],"Depression","2026-03-16",{"date":117,"type":39},"2026-03-19",{"date":119,"type":39},"2025-09-23",{"date":121,"type":22},"2026-12",{"name":123,"class":46},"American University of Beirut Medical Center",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":23,"phases":133,"briefSummary":134,"conditions":135,"keywords":140,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":96},"100431516","intermittent-fasting-for-nafld-in-adults-100431516","NCT04899102","Intermittent Fasting for NAFLD in Adults","Pilot Study of Time-Restricted, Intermittent Fasting for Non-Alcoholic Fatty Liver Disease in Non-Obese Adults","Inclusion Criteria:\n\n1. Willing and able to provide informed consent\n2. Age 18 years or older at time of consent\n3. BMI 23-30kg\u002Fm\\^2 at screening\n4. Evidence of NAFLD confirmed by historical procedure obtained no more than 6 months prior to the screening visit, defined as:\n\n   * Grade \\>=1 steatosis on clinical liver biopsy; OR\n   * Fatty liver on validated imaging modality (non-contrast CT scan, MR Spectroscopy, MRI proton density fat fraction, ultrasound)\n5. Liver fat fraction ≥10% on H-MRS performed during the screening period\n6. Hepatitis C antibody and Hepatitis B surface antigen negative at screening\n\nExclusion Criteria:\n\n1. Heavy alcohol use for at least 3 consecutive months within the past 5 years prior to screening \\[heavy alcohol consumption is defined as: \\> 20g daily for women or \\> 30mg daily for men, assessed by the Lifetime Drinking History assessment at screening (23, 24)\\].\n2. Evidence of other known forms of chronic liver disease including:\n\n   • Alcoholic liver disease, hepatitis B, hepatitis C, PBC, PSC, autoimmune hepatitis, Wilson disease, iron overload, alpha-1-antitrypsin deficiency, drug-induced liver injury, known or suspected hepatocellular carcinoma (HCC).\n3. Current or prior history of Type II Diabetes requiring insulin or sulfonylureas due to risk of hypoglycemia with fasting.\n4. Use of any pharmacological treatments for NAFLD\u002FNASH within the 6 months prior to the screening visit, except vitamin E. Patients on a stable dose of vitamin E can be enrolled in the study.\n5. Unstable body weight \\[defined as: \\>10% reduction in body weight in the 6 months prior to the screening visit\\]\n6. Known cirrhosis, stage 4 fibrosis on prior liver biopsy, or clinical evidence of cirrhosis or portal hypertension on imaging or exam.\n7. Current or prior history of Child-Pugh score ≥7.\n8. History of liver transplant, or current placement on a liver transplant list.\n9. Known positivity for human immunodeficiency virus infection.\n10. Prior or planned bariatric surgery, patients on active pharmacological treatment for weight loss, or active involvement in a weight loss program.\n11. Routine MRI exclusion criteria, such as the presence of a pacemaker or cerebral aneurysm clip.\n12. Chronic Kidney Disease (CKD) with eGFR \\\u003C 60.\n13. For women of child-bearing potential (WOCBP): positive urine hCG, trying to achieve pregnancy, or breastfeeding \\[a negative urine pregnancy test is required at screening for women of child-bearing potential\\].\n14. Other medical conditions or severe chronic illnesses that, in the opinion of the Investigator, may present a contraindication to study participation.\n15. Any other condition that, in the opinion of the Investigator, may hinder study compliance or completion of the study schedule of assessments.",{"count":132,"type":22},25,[25],"NAFLD is a growing threat to public health. Currently, there is a significant need for highly effective treatments for NAFLD. Non-obese NAFLD (BMI\\\u003C30kg\u002Fm2) is an increasingly recognized condition, sometimes described as \"lean NAFLD\". Intermittent Fasting (IF) may be uniquely beneficial in non-obese NAFLD. The purpose of this study is to identify non-pharmacologic, lifestyle-based methods of NAFLD treatment within non-obese adults.",[136,28,137,138,139],"Fatty Liver","Fatty Liver, Nonalcoholic","Non-Alcoholic Fatty Liver Disease","Liver Fat",[136,28,141,142,143,144,139,138,137],"Non-obese","Diet","Nutrition","Time-restricted","2025-12-10",{"date":147,"type":39},"2025-12-18",{"date":149,"type":39},"2022-02-01",{"date":151,"type":22},"2026-07-31",{"name":153,"class":46},"Massachusetts General Hospital",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":164,"briefSummary":165,"conditions":166,"keywords":169,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":96},"100541495","evaluation-of-the-efficiency-of-intermittent-enteral-nutrition-on-multi-organ-failure-from-patients-with-mechanical-ventilation-in-intensive-care-unit-100541495","NCT06330610","Evaluation of the Efficiency of Intermittent Enteral Nutrition on Multi-organ Failure From Patients With Mechanical Ventilation in Intensive Care Unit","Evaluation de l'efficacité du Support Nutritionnel entéral Intermittent Sur la défaillance d'Organes de Patients de réanimation Sous Ventilation assistée ENteral NUTrition - Continue Intermittent","ENNUT-CI","Inclusion Criteria:\n\n* Patient admitted in ICU for less than 48h, with invasive mechanical ventilation predicted for at least 48h, that can undergo nasogastric feeding for 7 days.\n* Patient under vasopressive drugs\n* Adult patients (age ≥ 18 years)\n* Informed person who has read and signed their consent\n\n  * If the patient is unable to sign their consent (emergency situation), the consent will be signed by a trusted person or a family member, and consent to continue the study will be requested subsequently.\n  * If the patient is unable to sign their consent (emergency situation) and no trusted person is present, the patient may be included in the study. In this case, consent to continue the study will be requested from a trusted person as soon as possible, or from the patient if they are able to understand and sign the consent.\n* Affiliation to a social security scheme\n* No current pregnancy: for women of childbearing age, a beta-HCG blood pregnancy test will be performed upon inclusion; for postmenopausal women, a confirmatory diagnosis must be obtained.\n\nExclusion Criteria:\n\n* Contraindication to enteral nutrition and\u002For nasogastric tube insertion: esophageal varices and occlusive syndrome\n* Artificial enteral nutrition that cannot be initiated within 48 hours of intubation\n* Enteral nutrition ongoing for more than one hour at the time of inclusion\n* Need for exclusive or supplemental parenteral nutrition\n* Moribund patient\n* Person deprived of liberty by an administrative or judicial decision or person placed under judicial protection\u002Fguardianship or curatorship\n* Pregnant or breastfeeding woman",{"count":163,"type":22},174,[25],"This study aims to evaluate the efficiency of intermittent enteral nutrition versus continuous enteral nutrition to prevent from organ failures for patients at the acute phase of sepsis shock with mechanical ventilation in ICU.",[28,167,168],"Septic Shock","Organ Failure, Multiple",[170,171,172,173,174],"Enteral nutrition","Mechanical ventilation","Intermittent fasting","Sepsis shock","Organ failure","2025-06-25",{"date":177,"type":39},"2025-06-29",{"date":179,"type":39},"2024-07-09",{"date":181,"type":22},"2027-10-09",{"name":183,"class":46},"University Hospital, Rouen",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":191,"targetDuration":4,"studyType":23,"phases":193,"briefSummary":194,"conditions":195,"keywords":199,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":96},"100589796","impact-of-intermittent-fasting-on-sleep-and-quality-of-life-100589796","NCT06959069","Impact of Intermittent Fasting on Sleep and Quality of Life","Impact of Intermittent Fasting on Sleep and Quality of Life Among Healthy Adults","Inclusion Criteria:\n\n* Healthy subjects\n* Adult subjects - age: between 18 and 65 years old\n* Subjects with a BMI between 18.5 and 29.9 kg\u002Fm\\^2\n* Male and female subjects\n\nExclusion Criteria:\n\n* Subjects \\\u003C 18 years old\n* Subjects with Diabetes Mellitus (type 1 and type 2)\n* Pregnant and\u002For breastfeeding and\u002For postpartum women\n* Underweight subjects (BMI \\\u003C 18.5)\n* Obese subjects (BMI \\> 30)\n* Subjects with confirmed sleep disorders (requiring CPAP or sleep medication (sleeping pills))\n* Subjects with renal failure (GFR \\\u003C 30 ml\u002Fmin\u002F1.73 m\\^2) or liver disorder\n* Subjects with serious cardiovascular, respiratory, neurological, or metabolic medical conditions\n* Subjects with malignant tumors\n* Subjects with a serious mental disorder requiring medication (e.g., antidepressants or anxiolytics)\n* Subjects with eating disorders\n* Subjects who have undergone major surgery or have been hospitalized due to major medical condition (surgery, stay in intensive care) within the last one year\n* Subjects who have lost more than 10% of their body weight within the last one year\n* Subjects actively participating in a weight-loss program\n* Subjects with alcohol use disorder (maximum 10 standard alcoholic drinks per week, 2 standard alcoholic drinks per day)\n* Subjects with substance use disorder\n* Subjects unable to provide informed consent\n* Subjects who do not participate simultaneously in another clinical trial",{"count":192,"type":22},36,[25],"The goal of this clinical trial is to investigate the impact of intermittent fasting on sleep, quality of life and fatigue among healthy volunteers. The main questions aim to answer:\n\nWhether intermittent fasting would allow participants to experience an improvement in their sleep quality, duration and latency? Whether intermittent fasting would ameliorate participants' quality of life and reduce chronic fatigue symptoms? Researchers will compare the two most prevailing fasting windows of intermittent diet including an early morning feeding window (8 a.m.-4 p.m.) and a late feeding window (12 p.m.-8 p.m.) to see if there is a difference among these feeding windows on sleep and quality of life.\n\nParticipants will:\n\n* Be divided into two groups (group A and group B) that will alternate their fasting windows.\n* Group A will start with intermittent fasting over a feeding period from 12 p.m. to 8 p.m. for one month, then a two weeks period of usual eating habits (washout period) and finally one month of intermittent fasting with a feeding period from 8 a.m. to 4 p.m.\n* Group B will follow intermittent fasting over a feeding period from 8 a.m. to 4 p.m for one month, then a two weeks period of usual eating habits (washout period) and finally one month of intermittent fasting with a feeding period from 12 p.m. to 8 p.m.\n* At enrollment, at the end of each month of intermittent fasting and at the end of washout period participants will be asked to complete some questionnaires and will be submitted to anthropometric measurements using impedance scales.\n* Participants will be asked to complete an electronic 24 hour recall diary using the Automated Self-Administered 24h Dietary Assessment (ASA24) Tool software once per week every week during study.",[196,197,198,28],"Sleep Quality","Quality of Life","Fatigue",[34,200,201,202],"sleep","quality of life","fatigue","2025-04-27",{"date":205,"type":39},"2025-05-06",{"date":207,"type":39},"2025-03-17",{"date":209,"type":22},"2026-08-30",{"name":211,"class":46},"Université Libre de Bruxelles",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":220,"enrollmentInfo":221,"targetDuration":4,"studyType":23,"phases":223,"briefSummary":224,"conditions":225,"keywords":228,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":96},"100540979","longitudinal-monitoring-during-intermittent-fasting-protocols-in-obese-adults-100540979","NCT06323889","Longitudinal Monitoring During Intermittent Fasting Protocols in Obese Adults","Longitudinal Monitoring During Different Intermittent Fasting Protocols in Obese Adults - a Randomized Clinical Trial","LIMITFOOD2","Inclusion Criteria:\n\n* Age between 18-50 years, both inclusive\n* Obese, BMI between 30 and 40 kg\u002Fm\\^2 (obesity grade I or II), both inclusive\n* Non-smoker\n* Good knowledge of German or English language\n* Stable weight change (change \\\u003C +\u002F- 3% current bodyweight) for 3 months prior to the study\n* HbA1c \\\u003C 6.5% without glucose lowering medication\n* LDL-cholesterol \\\u003C 4.6mmol\u002Fl without lipid lowering medication\n\nExclusion Criteria:\n\n* Participants who have a fasting period of \\> 12h per day on a regular basis and do not eat at least three main meals per day.\n* Current habitual use of dietary supplements (e.g., vitamins, minerals) and\u002For unwillingness to cease intake of dietary supplements.\n* Antibiotics intake during 3 months prior to the study due to possible interference with metabolic parameters\n* Food intolerances, allergies and sensitivities (severe food allergies) or dietary restrictions (e.g. vegan lifestyle)\n* Acute or chronic infections, malignant disease, renal, hepatic (more than two-fold increased transaminases), pulmonary, neurological (epilepsy) or psychiatric diseases, manifested atherosclerosis, or any other disease precluding participation in the study.\n* Diabetes\n* Known alcohol, substance or drug abuse, concomitant medication\n* More than four hours of physical exercise per week\n* Women who are pregnant, breast-feeding or aiming to become pregnant during course of the trial\n* Women and men on hormonal supplementation\n* Women with an irregular menstrual cycle according to the FIGO criteria\n* Therapy with antidepressants within the past 6 months\n* Regular therapy with acetylsalicyclic acid or current medication to regulate blood sugar, blood pressure or lipids\n* Participants likely to fail to comply with the study protocol\n* Participants who do not give informed consent","50 Years",{"count":222,"type":22},90,[25],"LIMITFOOD2 is a randomized clinical intervention study that investigates the effects of two different intermittent fasting protocols compared to a control group on the health of obese adults. A total of 90 participants will be randomized into three equally sized groups: a modified alternate day fasting, a time-restricted eating and a control group, receiving general weight-loss counseling.",[28,226,227],"Obesity","Time Restricted Eating",[229,230,231,226,232],"Overnutrition","Nutrition Disorders","Body Weight","Longitudinal monitoring","2024-12-17",{"date":235,"type":39},"2024-12-20",{"date":237,"type":39},"2024-09-23",{"date":239,"type":22},"2027-01",{"name":241,"class":46},"University of Zurich",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":16,"sex":17,"minAge":250,"maxAge":19,"enrollmentInfo":251,"targetDuration":4,"studyType":23,"phases":252,"briefSummary":253,"conditions":254,"keywords":257,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":4},"100563411","intermittent-fasting-mediterranean-diet-and-nafld-100563411","NCT06615817","Intermittent Fasting, Mediterranean Diet and NAFLD","Comparison Between 14\u002F10 Intermittent Fasting and the Southern Italian Mediterranean Diet in the Variation of NAFLD Score, Inflammatory Indices and Intestinal Microbiota","RC2024-21","Inclusion Criteria:\n\n* Medium\u002Fsevere NAFLD (CAP\\>268)\n* BMI between 25 and 35\n\nExclusion Criteria:\n\n* diabetes treated with insulin,\n* fatty liver disease linked to alcohol consumption,\n* chronic inflammatory intestinal and oncological diseases,\n* visceral obesity which does not allow good resolution of Fibroscan images,\n* subjects in serious medical conditions that may compromise participation in the trial,\n* people following a special diet or unable to follow a diet for religious or other reasons.\n* Pregnancy and breastfeeding","30 Years",{"count":21,"type":22},[25],"This study aims to evaluate the effects of Intermittent Fasting (IF) 14\u002F10 compared with the Low Glycemic Index Mediterranean Diet on NAFLD.",[255,226,28,256],"NAFLD","Mediterranean Diet",[226,258],"Liver Diseases","2024-10-22",{"date":261,"type":39},"2024-10-26",{"date":263,"type":22},"2025-01-01",{"date":265,"type":22},"2027-01-01",{"name":267,"class":46},"Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis",{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":274,"eligibilityCriteria":275,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":23,"phases":278,"briefSummary":279,"conditions":280,"keywords":286,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":96},"100497676","intermittent-fasting-versus-carbohydrate-drinks-before-surgery-100497676","NCT05760339","Intermittent Fasting Versus Carbohydrate Drinks Before Surgery","Preoperative Intermittent Fasting Versus Carbohydrate Loading to Reduce Insulin Resistance: a Randomised Controlled Trial","PRINCESS","Inclusion Criteria:\n\n* Undergoing elective orthopaedic surgery;\n* Intermediate, major or complex surgery according to the Surgical Outcome Risk Tool (SORT; http:\u002F\u002Fwww.sortsurgery.com\u002F) severity of surgery classification;\n* Scheduled for surgery at least 17 days from the date of screening;\n* Motivated to follow a time restricted feeding regimen.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* History of diabetes mellitus;\n* History of feeding or eating disorders;\n* History of delayed gastric emptying or gastro-oesophageal reflux\n* Active malignancy\n* Patients classified as ASA IV by the attending anaesthetist;\n* BMI \\\u003C 18.5 or ≥ 35;\n* Outpatient or day case surgery;\n* Palliative surgery;\n* Participation in another clinical trial that is interfering with the procedures or outcomes of the PRINCESS trial;\n* Patients unable to fully comply to study needs (e.g. legally incapable patients or patients unable to communicate in Dutch).",{"count":277,"type":22},75,[25],"The purpose of this study is to investigate whether time-restricted feeding, a form of intermittent fasting, before surgery improves insulin resistance around the time of surgery, compared to carbohydrate drinks and standard fasting before surgery.",[281,28,282,283,284,285],"Perioperative Care","Carbohydrate Loading","Preoperative Fasting","Orthopedic Surgery","Insulin Resistance",[281,282,284,285,287,288],"HOMA-IR","Time Restricted Feeding","2024-10-18",{"date":259,"type":39},{"date":292,"type":39},"2023-03-20",{"date":294,"type":22},"2025-09",{"name":296,"class":46},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":103,"minAge":18,"maxAge":19,"enrollmentInfo":304,"targetDuration":4,"studyType":23,"phases":306,"briefSummary":307,"conditions":308,"keywords":310,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":96},"100558047","intermittent-fasting-and-mediterranean-diet-in-patient-with-multiple-sclerosis-100558047","NCT06546033","Intermittent Fasting and Mediterranean Diet in Patient With Multiple Sclerosis","Determination of the Effects of Intermittent Fasting and Mediterranean Diet on Quality of Life, Circadian Rhythm and Appetite Markers in Patient With Multiple Sclerosis","Inclusion Criteria:\n\n* To apply to the neurology outpatient clinic, to be a female between the ages of 18-65 who has been diagnosed with MS by a physician\n* Not being in the attack period\n* Not being in menopause Not being diagnosed with any autoimmune system disease other than -MS that may adversely affect the study,\n* Not following the Mediterranean diet and intermittent fasting programmes in the last three months,\n* Not being diagnosed with an eating behaviour disorder,\n* Not having any communication problems,\n* Signing the informed consent form,\n* Brain MRI within the last three months,\n* Not to be pregnant and lactating\n* No physical disability No history of cancer\n* Body Mass Index between 18,5 kg\u002Fm2- 29,9 kg\u002Fm2,\n* Not losing 5% and\u002For more body weight in the last month\n\nExclusion Criteria:\n\n* Having a diagnosis of autoimmune system disease that may adversely affect working outside of -MS,\n* To be in the attack period-Being under 18 years of age and over 65 years of age\n* Being in menopause-Mediterranean diet and intermittent fasting feeding programmes within the last three months,\n* Diet therapy that has an effect on the autoimmune system within the last three months,\n* Being diagnosed with eating behaviour disorder,\n* Having any communication problems,- Not signing the informed consent form,\n* Failure to adapt to the work during the working period, to be in a situation\u002Fbehaviour that may adversely affect the work,\n* To have applied any nutritional intervention during the last three months prior to the study,\n* Taking supplements such as selenium, zinc, iron, vitamin D and\u002For B12, which may affect the course of the study,\n* To have received cancer treatment and \u002F or to be receiving cancer treatment,\n* Other neurological diseases (e.g. Parkinson's, epilepsy, Alzheimer's),\n* Diagnosed with a disease lasting more than 4 months in the last 12 months and other specialised dietary \u002F compositionally different dietary patterns (e.g. high protein, ketogenic, low energy content \\\u003C 1000 kcal\u002Fday),\n* Body Mass Index \\\u003C18.5 kg\u002Fm2 or \\>30 kg\u002Fm2\n* Losing 5% and\u002For more body weight in the last month,\n* Having a physical disability",{"count":305,"type":22},34,[25],"When the literature was reviewed, there is no study in which the effects of intermittent fasting and Mediterranean diet on quality of life, sleep, circadian rhythm and appetite hormones leptin and ghrelin levels in MS patients were evaluated and the two diet types were comparatively examined in terms of all these parameters.",[309,28],"Multiple Sclerosis",[311,312,313,28],"Multiple sclerosis","circadian rhythm","mediterranean diet","2024-08-05",{"date":316,"type":39},"2024-08-09",{"date":318,"type":39},"2024-05-02",{"date":320,"type":22},"2026-12-02",{"name":322,"class":46},"Nigde Omer Halisdemir University",{"id":324,"slug":325,"hasResults":11,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":16,"sex":103,"minAge":18,"maxAge":54,"enrollmentInfo":330,"targetDuration":4,"studyType":23,"phases":332,"briefSummary":333,"conditions":334,"keywords":335,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":96},"100555143","time-restricted-eating-and-cognition-100555143","NCT06508255","Time-restricted Eating and Cognition","Time-restricted Eating and Cognition (ChronoBEAT)","Inclusion Criteria:\n\n* right-handed\n* legally competent\n* physically and mentally healthy\n* BMI: 19-35 kg\u002Fm²\n* fluent in reading and speaking German\n\nExclusion Criteria:\n\n* weight change \\>5% of body weight during the last 3 months\n* pregnancy or breastfeeding\n* allergies (inclusion possible after consultation with study doctor)\n* history of cardiovascular disease (myocardial infarction, stroke, hypertension, hypotension) in the last year\n* severe psychiatric condition, including drug addiction and depression\n* impaired renal or liver function\n* dementia or other severely debilitating cognitive disease\n* history of or current eating disorders (e.g., Bulimia nervosa, Anorexia nervosa, Orthorexia nervosa, Binge-Eating disorder)\n* chronic diseases (e.g., Morbus Crohn, Colitis Ulcerosa)\n* metabolic disorders (e.g., metabolic syndrome, diabetes type 1 or 2)\n* hormonal imbalances (e.g., thyroid gland diseases)\n* consuming diseases (e.g., cancer, kachexie) in the last 2 years\n* surgical removal (partial removal) of the digestive organs (e.g., gastrectomy) or history of bariatric surgery\n* Autoimmune conditions or current infection\n* Blood clotting disorders (e.g., haemophilia)\n* Severe anemia\n* severe claustrophobia\n* blood donation four weeks prior to study entry\n* glucocorticoid therapy (oral)\n* anticoagulant medication (inclusion possible if medication can be paused)\n* taking medications that require regular eating\n* any medications or supplements known to affect sleep, circadian rhythms, immune activity or metabolism\n* taking weight loss, lipid or glucose-lowering medications (any medications that affects metabolism) i.e. metformin\n* pacemaker or other electrical implant\n* vaccination during the study course or in the two weeks' prior\n* immunosuppressive premedication\n* currently on a diet\u002Ffasting regime (or within 1 month)\n* professional athletes\n* nicotine consumption\n* drug abuse\n* alcohol consumption per week more than 14 beers (0,3l)\u002F wine (0,125l)\u002F sparkling wine (0,1l)\u002FSchnaps (4cl)\n* shift work\n* poor sleep quality (PSQI score \\> 10 at medical screening)\n* travel across more than one time zone one month before study or during study period\n* non-removable metallic implants\n* fear of blood draw",{"count":331,"type":22},35,[25],"This study aims to investigate how time-restricted eating (TRE), more specifically TRE at different times (early vs late in the day), influences brain activity, behavior, decision-making, food intake, physical activity, the gut microbiome and metabolic processes. The study intervention procedure is a replication of that described in Peters et al. (2021).",[227,28],[336,337,338,339,340,341,342,142,343,344,345],"Time-restricted eating","Time-restricted feeding","Cognition","Decision-making","Behaviour","Brain Activity","Food Intake","Microbiome","Sleep","Physical Activity","2024-07-17",{"date":348,"type":39},"2024-07-18",{"date":350,"type":39},"2024-05-17",{"date":352,"type":22},"2025-03",{"name":354,"class":46},"German Institute of Human Nutrition"]